{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T17:48:20Z","timestamp":1775065700324,"version":"3.50.1"},"reference-count":35,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2007,1,24]],"date-time":"2007-01-24T00:00:00Z","timestamp":1169596800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatric Blood &amp; Cancer"],"published-print":{"date-parts":[[2007,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>Demonstrate that high\u2010dose cyclophosphamide (CY) is effective therapy for hepatitis\u2010associated aplastic anemia (HAA).<\/jats:p><\/jats:sec><jats:sec><jats:title>Background<\/jats:title><jats:p>HAA is a sequence of seronegative hepatitis followed by aplastic anemia. Optimal treatment is matched\u2010sibling allogeneic bone marrow transplantation (BMT). The combination of antithymocyte globulin (ATG) and cyclosporine (CSA) has also been studied, but there are scarce data regarding treatment of HAA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Procedure<\/jats:title><jats:p>Five patients (median age 14 years; range 6\u201317 years) with HAA and without an HLA\u2010matched sibling were treated with high\u2010dose CY (50 mg\/kg\/day IV\u2009\u00d7\u20094 days) followed by granulocyte\u2010colony stimulation factor (G\u2010CSF).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>After at least 1 year of follow\u2010up, four of five patients are in remission without further immune suppression beyond high\u2010dose CY. Of the 4 responders, median time to absolute neutrophil count (ANC) &gt;500 \u00b5l<jats:sup>\u22121<\/jats:sup> was 51 days (range 44\u2013369). Median time to transfusion independence for erythrocytes and platelets was 109 (range 57\u2013679) and 160 (range 48\u2013679) days, respectively. The fifth patient did not respond and proceeded to an unrelated donor transplant. One patient met criteria for autoimmune hepatitis (AIH) in addition to HAA. In this case, high\u2010dose CY successfully induced remission of both diseases.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>High\u2010dose CY induces durable remissions in HAA and may be an effective treatment for AIH. Pediatr Blood Cancer 2007;49:947\u2013951. \u00a9 2007 Wiley\u2010Liss, Inc.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pbc.21143","type":"journal-article","created":{"date-parts":[[2007,1,25]],"date-time":"2007-01-25T05:03:31Z","timestamp":1169701411000},"page":"947-951","source":"Crossref","is-referenced-by-count":22,"title":["Treatment of hepatitis\u2010associated aplastic anemia with high\u2010dose cyclophosphamide"],"prefix":"10.1002","volume":"49","author":[{"given":"William J.","family":"Savage","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia A.","family":"DeRusso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda M.","family":"Resar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allen R.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meghan A.","family":"Higman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David M.","family":"Loeb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard J.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert A.","family":"Brodsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,1,24]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)66515-4"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199704103361504"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0508124102"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.thj.6200215"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V53.3.504.504"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-126-2-199701150-00003"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.10752"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.10400"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-135-7-200110020-00006"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-01-0087"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V75.8.1646.1646"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1990.tb06339.x"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-197554020-00003"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-11-3959"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1992.03480150057037"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(99)80297-9"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-1746.2001.02615.x"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra050408"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510250237"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1702749"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198808183190702"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1432-2277.2002.tb00138.x"},{"key":"e_1_2_5_24_2","article-title":"Immunotherapy for severe aplastic anemia following orthotopic liver transplantation in children","author":"Sanchez R","year":"2006","journal-title":"Pediatr Blood Cancer"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)03126-3"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-02-0494"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2004.04917.x"},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)04278-1"},{"key":"e_1_2_5_29_2","first-page":"E06","article-title":"Treatment of severe aplastic anemia using high\u2010dose cyclophosphamide alone in China","volume":"85","author":"Li Z","year":"2000","journal-title":"Haematologica"},{"key":"e_1_2_5_30_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.2.491.bloodjournal872491"},{"key":"e_1_2_5_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2004.02.002"},{"key":"e_1_2_5_32_2","doi-asserted-by":"publisher","DOI":"10.1002\/1096-8652(200101)66:1<71::AID-AJH1019>3.0.CO;2-D"},{"key":"e_1_2_5_33_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197612302952708"},{"key":"e_1_2_5_34_2","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V106.11.129.129","article-title":"High dose cyclophosphamide (CY) for severe aplastic anemia (SAA): Safety and long term follow\u2010up","volume":"106","author":"Brodsky RA","year":"2005","journal-title":"Blood"},{"key":"e_1_2_5_35_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V85.11.3058.bloodjournal85113058"},{"key":"e_1_2_5_36_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-03-0874"}],"container-title":["Pediatric Blood &amp; Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.21143","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.21143","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pbc.21143","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/pbc.21143","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pbc.21143","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T19:58:51Z","timestamp":1694030331000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pbc.21143"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,1,24]]},"references-count":35,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2007,12]]}},"alternative-id":["10.1002\/pbc.21143"],"URL":"https:\/\/doi.org\/10.1002\/pbc.21143","archive":["Portico"],"relation":{},"ISSN":["1545-5009","1545-5017"],"issn-type":[{"value":"1545-5009","type":"print"},{"value":"1545-5017","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,1,24]]}}}